Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
CD20 expression: A risk stratification factor for newly diagnosed multiple myeloma with t(11;14)
View through CrossRef
ObjectiveTranslocation (11;14) is one of the most frequent recurrent cytogenetic abnormalities in multiple myeloma (MM), while its clinical prognostic value remains controversial. CD20 expression is uncommon in MM while strongly associated with t(11;14). This study aimed to investigate whether CD20 could provide further prognostic value in MM patients harboring t(11;14).MethodsCD20 expression detected by flow cytometry was retrospectively analyzed in 211 newly diagnosed MM patients with t(11;14). The clinical characteristics and outcomes were analyzed between CD20 positive and negative patients.ResultsCD20 expression was found in 34.6% (73/211) newly diagnosed MM (NDMM) patients with t(11;14), associated with lower serum creatine levels and lower incidence of plasmacytoma. Based on similar treatment regimens, CD20 positive patients had a comparable overall response rate to CD20 negative patients, whereas had a lower CR/sCR (complete response/stringent complete response) rate than the latter (31.4% vs. 46.4%, P =0.045). Nevertheless, CD20 positive patients had a longer tendency of progression-free survival (PFS) (59.0 vs. 29.0 months, P =0.163) and significantly longer overall survival (OS) (99.0 vs. 56.0 months, P=0.003) than CD20 negative patients. Further investigation among CD20 expression proportion showed that strong expression of CD20 (>80% of bone marrow plasma cells) exhibited the longest OS (median not reached, P =0.011). However, the favorable impact of CD20 expression on survival was eliminated with the contaminant presence of cytogenetic abnormalities besides t(11;14). Autologous stem cell transplantation (ASCT) could improve the prognosis of CD20 negative t(11;14) patients. Multivariate analysis confirmed that CD20 expression was an independent favorable indicator for longer OS in t(11;14) MM patients.ConclusionCD20 expression is a favorable prognostic factor in NDMM with t(11;14) and could provide further risk-stratification value in this heterogeneous disease subgroup.
Title: CD20 expression: A risk stratification factor for newly diagnosed multiple myeloma with t(11;14)
Description:
ObjectiveTranslocation (11;14) is one of the most frequent recurrent cytogenetic abnormalities in multiple myeloma (MM), while its clinical prognostic value remains controversial.
CD20 expression is uncommon in MM while strongly associated with t(11;14).
This study aimed to investigate whether CD20 could provide further prognostic value in MM patients harboring t(11;14).
MethodsCD20 expression detected by flow cytometry was retrospectively analyzed in 211 newly diagnosed MM patients with t(11;14).
The clinical characteristics and outcomes were analyzed between CD20 positive and negative patients.
ResultsCD20 expression was found in 34.
6% (73/211) newly diagnosed MM (NDMM) patients with t(11;14), associated with lower serum creatine levels and lower incidence of plasmacytoma.
Based on similar treatment regimens, CD20 positive patients had a comparable overall response rate to CD20 negative patients, whereas had a lower CR/sCR (complete response/stringent complete response) rate than the latter (31.
4% vs.
46.
4%, P =0.
045).
Nevertheless, CD20 positive patients had a longer tendency of progression-free survival (PFS) (59.
0 vs.
29.
0 months, P =0.
163) and significantly longer overall survival (OS) (99.
0 vs.
56.
0 months, P=0.
003) than CD20 negative patients.
Further investigation among CD20 expression proportion showed that strong expression of CD20 (>80% of bone marrow plasma cells) exhibited the longest OS (median not reached, P =0.
011).
However, the favorable impact of CD20 expression on survival was eliminated with the contaminant presence of cytogenetic abnormalities besides t(11;14).
Autologous stem cell transplantation (ASCT) could improve the prognosis of CD20 negative t(11;14) patients.
Multivariate analysis confirmed that CD20 expression was an independent favorable indicator for longer OS in t(11;14) MM patients.
ConclusionCD20 expression is a favorable prognostic factor in NDMM with t(11;14) and could provide further risk-stratification value in this heterogeneous disease subgroup.
Related Results
Understanding CD20 Regulation By Loss-Of-Function RNAi Screen
Understanding CD20 Regulation By Loss-Of-Function RNAi Screen
Abstract
Introduction
CD20 is a cell surface glycoprotein, encoded by the MS4A1 gene, which is highly expressed on most B-cells....
Supplementary Data from Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors
Supplementary Data from Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors
<p>Supplementary Methods, Supplementary Figures S1-S15 Fig. S1. Purification and binding specificity of MV-encoded BiTEs. (A) Purification of MV-expressed BiTEs. Vero cells w...
Papillary thyroid carcinoma expressing CD20
Papillary thyroid carcinoma expressing CD20
We identified a case of lymphadenopathy of metastatic papillary thyroid carcinoma (PTC) with CD20 expression, which was also expressed by the primary tumor. CD20 expression was ide...
ANALISIS PERTIMBANGAN MAHKAMAH AGUNG DALAM MENGABULKAN KASASI TERDAKWA (STUDI PUTUSAN NOMOR 2959/K/PID.SUS/2022)
ANALISIS PERTIMBANGAN MAHKAMAH AGUNG DALAM MENGABULKAN KASASI TERDAKWA (STUDI PUTUSAN NOMOR 2959/K/PID.SUS/2022)
<p><em><span class="markedContent"><span style="left: calc(var(--scale-factor)*195.53px); top: calc(var(--scale-factor)*496.87px); font-size: calc(var(--scale-...
Anti‐CD20 monoclonal antibody therapy in multiple myeloma
Anti‐CD20 monoclonal antibody therapy in multiple myeloma
SummaryCD20 is a particularly appealing target that is expressed on the surface of almost all B cells, with no significant shedding, secretion or internalization. In contrast to th...
Seorang laki-laki dewasa muda dengan multiple myeloma monoklonal gamopati lambda: sebuah laporan kasus
Seorang laki-laki dewasa muda dengan multiple myeloma monoklonal gamopati lambda: sebuah laporan kasus
Introduction: Multiple myeloma is the second most common hematological malignancy after non-Hodgkin's lymphoma with a case prevalence in Prof. Dr. I.G.N.G. Ngoerah Hospital for the...
Fine Tuning Bispecific Activity in CLL: Harmonizing a CD19/20-T Cell Bispecific with a CD28 or 4-1BBL Costimulatory Bispecific
Fine Tuning Bispecific Activity in CLL: Harmonizing a CD19/20-T Cell Bispecific with a CD28 or 4-1BBL Costimulatory Bispecific
Introduction:
T cell bispecific antibodies (TCBs), such as blinatumomab, mosunetuzumab or glofitamab, redirect T cells toward cancer cells and rely on endogenous T c...
Data from Functional B7.2 and B7-H2 Molecules on Myeloma Cells Are Associated with a Growth Advantage
Data from Functional B7.2 and B7-H2 Molecules on Myeloma Cells Are Associated with a Growth Advantage
<div>Abstract<p><b>Purpose:</b> B7 family molecules expressed on antigen-presenting cells stimulate or inhibit normal immune responses. The aim of this stud...